Next Article in Journal
The Compositional HJ-Biplot—A New Approach to Identifying the Links among Bioactive Compounds of Tomatoes
Previous Article in Journal
Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation
Previous Article in Special Issue
Assessing Heterogeneity of Osteolytic Lesions in Multiple Myeloma by 1H HR-MAS NMR Metabolomics
Article

The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts

Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy
*
Author to whom correspondence should be addressed.
The authors contributed equally to this work.
Academic Editor: Maria Alfonsina Desiderio
Int. J. Mol. Sci. 2016, 17(11), 1827; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17111827
Received: 30 June 2016 / Revised: 21 October 2016 / Accepted: 27 October 2016 / Published: 1 November 2016
(This article belongs to the Special Issue Cellular and Molecular Mechanisms of Bone Metastasis)
Metastatic bone disease has a major impact on morbidity of breast cancer (BC) patients. Alterations in mTOR signaling are involved both in cancer progression and in osteoclast differentiation. The purpose of this study was to assess the role of mTOR inhibitor Everolimus (Eve) on osteoclastogenesis induced by triple negative BC cells. To this aim, we developed an in vitro human model of osteoclastogenesis from peripheral blood monocytes co-cultured with the triple negative SCP2 and the hormonal receptor positive MCF7 cell lines. Osteoclastogenesis was evaluated by TRAP staining, evaluation of F actin rings and Calcitonin Receptor expression. Eve significantly reduced differentiation induced by cancer cells and resulted more effective when evaluated in combination with Denosumab and Zoledronic Acid (Zol). Combination with Zol showed a total abrogation of osteoclast differentiation induced by the triple negative cell line, not by MCF7. Finally, we observed that Eve was active in the inhibition of the crosstalk between cancer cells and osteoclasts reproduced by our model, highlighting a new therapeutic choice for the subsetting of triple negative BC patients. We observed a difference in the response to bone-targeted therapy with respect to BC subtypes. Our model may represent a valid platform for preclinical trials on bone-targeted drugs and for the study of the interplay of BC with bone stromal cells. View Full-Text
Keywords: breast cancer; bone metastasis; everolimus; triple negative breast cancer; bone metastasis; everolimus; triple negative
Show Figures

Graphical abstract

MDPI and ACS Style

Mercatali, L.; Spadazzi, C.; Miserocchi, G.; Liverani, C.; De Vita, A.; Bongiovanni, A.; Recine, F.; Amadori, D.; Ibrahim, T. The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts. Int. J. Mol. Sci. 2016, 17, 1827. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17111827

AMA Style

Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T. The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts. International Journal of Molecular Sciences. 2016; 17(11):1827. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17111827

Chicago/Turabian Style

Mercatali, Laura, Chiara Spadazzi, Giacomo Miserocchi, Chiara Liverani, Alessandro De Vita, Alberto Bongiovanni, Federica Recine, Dino Amadori, and Toni Ibrahim. 2016. "The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts" International Journal of Molecular Sciences 17, no. 11: 1827. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17111827

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop